CoChat

Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab

Open access
Liu, Enchi, Wang, Dai, Sperling, Reisa, Salloway, Stephen, Fox, Nick C., Blennow, Kaj, Scheltens, Philip, Schmidt, Mark E., Streffer, Johannes, Novak, Gerald, Einstein, Steve, Booth, Kevin, Ketter, Nzeera, Brashear, H. Robert, For the ELN115727-301/302 Investigator Group, ELN115727-301/302 Investigator Group, Chair, S. Salloway, Sperling, R., Raskind, M., Sabbagh, M., Honig, L., Porsteinsson, A., Ferris, S., Weisman, D., McCartney, M., Iqbal, N., Dietrich, D., Miller, T., Hermann-Gertz, J., Zimmerman, E., Forchetti, C., Dempsey, G.M., Ettigi, P., Jacobson, A., Zacharis, A., Shua-Haim, J., Mehra, V., Markind, S., Zagar, D., Thompson, J., Alva, G., Fuller, W., Rodd, J., Steen, S., Tariot, P., Sabbagh, M., Doody, R., Severa, L., Green, P., Stern, R., McElveen, W., Brody, M., Marshall, G., Seiden, D., Frank, A., Salloway, S., Kinney, F., Litman, R., Soufer, J., Edelsohn, L., Lesem, M., Bernick, C., Kluge, R., Biton, V., DeSantis, M., Wang, X., Usher, G., Morin, C., Omidvar, O., Honig, L., Curtis, C., Licht, J., Coffey, D., Anderson, C., Nash, M., Stein, M., Germain, M., Nair, V., Lippa, C., Beyer, J., Richardson, B., Moore, N., Vidic, T., Igleburger, J., Levey, A., Edwards, K., Steiner, D., Chang, F., Long, J., Turner, R., Apter, J., Barnhart, B., Nash, M., Schwartz, R., Shatz, R., Robillard, A., Garcia, A., Kohlenberg, C., Matthews, B., Chehrenama, H., Garrison, J., Shiwach, R., Jennings, D., Gazda, S., Davtian, Ar., Booker, J., Rovner, B., Goldenberg, J., Raj, A., Rosenberg, P., Watkins, F., Ingram, J., Chertkow, H., Yadalam, K., Applebaum, J., Biunno, M., Minagar, A., Rujescu, D., Randhawa, S., Dinnerstein, E., Margolin, D., Graff-Radford, N., Knopman, D., Antuono, P., Wilks, K., Du Preez, M., Lichtenstein, T., Barkhuizen, F., Thebaud, A., Liss, J., Mintzer, J., Dal-Bianco, P., Schmidt, R., Gold, S., Farmer, M., Agronin, M., Kohrman, B., Bozoki, A., Kapper, J., Winegarner, D., English, J., Grossman, H., Pomara, N., Murman, D., Spikol, L., Malhotra, S., Biber, M., Burkholder, J., Tramontano, G., Harris, J., Holub, R., Kudrow, D., Honeycutt, W., Waldman, S., Kittur, S., Stein, L., Gerard, G., Cohen, S., Goldstick, L., Chueh, D., Schaerf, F., Nasreddine, Z., Ellis, J., Nash, M., Shubin, R., Gywnn, M., Barker, J., Wendt, J., Mesulam, M., Sadowski, M., Quinn, J., Mikszewski, J., Tuchman, M., Foley, C., Borrie, M., Arnold, S., Rousseau, R., Oskooilar, N., Grosz, D., Wilcox, C., Kwentus, J., Sadowsky, C., Mega, M., Carlini, W., Ranjan, R., Bowman, M., Chakraburtty, A., Nardandrea, J., Sloan, B., Ott, B., Stoukides, J., Keegan, A., Bettinger, I, Grossberg, G., Goldstein, J., Itzcovich-Schuster, J., Winston, J., Feldman, R., Plopper, M., Ferencz, G., Ala, T., Vatakis, N., Montoya, L., Rossen, M., Stedman, M., Pasternak, S., Losk, S., Cohen, S., Ginsberg, P., Ng, B., Au, W., Dolnak, D., Tunell, G., Marotta, G., Ervin, J., Kalafer, M, Solomon, P., Ross, J., Scharre, C., Lobatz, M., Hubbard, R., Lerner, A., Ahern, G., Patry, D., DeCarli, C., Grill, J., Boxer, A., Brewer, J., Preda, A., Mastrianni, J., Burns, J., Jicha, G., Fishman, P., Chopra, A., Barbas, N., Ford, C., Lopez, O., Porsteinsson, A., Smith, A., Auchus, A., Rosenberg, R., Eschweiler, G., Riepe, M., von Arnim, C., Zamrini, E., Dekosky, S., Pendelbury, W., Asthana, S., Hart, D., Raskind, M., Trader, D., Dougherty, J., Vine, D., Carr, D., Tornabene, J., Keren, R., van Dyck, C. · 2018 · Neurology
Cited by 44

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

Objective To evaluate whether amyloid-related imaging abnormalities with edema/effusion (ARIA-E) observed in bapineuzumab clinical trials was associated with specific biomarker patterns. Methods Bapineuzumab, an anti-β-amyloid monoclonal antibody, was evaluated in patients with mild to moderate Alzheimer disease. Amyloid PET imaging, CSF biomarkers, or volumetric MRI (vMRI) were assessed. Results A total of 1,512 participants underwent one or more biomarker assessments; 154 developed incident ARIA-E. No differences were observed at baseline between ARIA-E and non-ARIA-E participants in brain amyloid burden by PET, the majority of vMRI measures, or CSF biomarkers, with the exception of lower baseline CSF Aβ42 in APOE ε4 noncarrier ARIA-E vs non-ARIA-E groups (bapineuzumab non-ARIA-E p = 0.027; placebo non-ARIA-E p = 0.012). At week 71, bapineuzumab-treated participants with ARIA-E vs non-ARIA-E showed greater reduction in brain amyloid PET, greater reductions in CSF phosphorylated tau (p-tau) (all comparisons p < 0.01), and total tau (t-tau) (all comparisons p < 0.025), and greater hippocampal volume reduction and ventricular enlargement (all p < 0.05). Greater reduction in CSF Aβ40 concentrations was observed for ARIA-E versus both non-ARIA-E groups (bapineuzumab/placebo non-ARIA-E p = 0.015/0.049). No group differences were observed at week 71 for changes in whole brain volume or CSF Aβ42. Conclusions Baseline biomarkers largely do not predict risk for developing ARIA-E. ARIA-E was associated with significant longitudinal changes in several biomarkers, with larger reductions in amyloid PET and CSF p-tau and t-tau concentrations, and paradoxically greater hippocampal volume reduction and ventricular enlargement, suggesting that ARIA-E in bapineuzumab-treated cases may be related to increased Aβ efflux from the brain and affecting downstream pathogenic processes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1212/wnl.0000000000005060

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Cited by

See all 44

Metadata

Authors
Liu, E., Wang, D., Sperling, R., Salloway, S., Fox, N. C., Blennow, K., Scheltens, P., Schmidt, M. E., Streffer, J., Novak, G., Einstein, S., Booth, K., Ketter, N., Brashear, H. R., For the ELN115727-301/302 Investigator Group, ELN115727-301/302 Investigator Group, Chair, S. S., Sperling, R., Raskind, M., Sabbagh, M., Honig, L., Porsteinsson, A., Ferris, S., Weisman, D., McCartney, M., Iqbal, N., Dietrich, D., Miller, T., Hermann-Gertz, J., Zimmerman, E., Forchetti, C., Dempsey, G. M., Ettigi, P., Jacobson, A., Zacharis, A., Shua-Haim, J., Mehra, V., Markind, S., Zagar, D., Thompson, J., Alva, G., Fuller, W., Rodd, J., Steen, S., Tariot, P., Sabbagh, M., Doody, R., Severa, L., Green, P., Stern, R., McElveen, W., Brody, M., Marshall, G., Seiden, D., Frank, A., Salloway, S., Kinney, F., Litman, R., Soufer, J., Edelsohn, L., Lesem, M., Bernick, C., Kluge, R., Biton, V., DeSantis, M., Wang, X., Usher, G., Morin, C., Omidvar, O., Honig, L., Curtis, C., Licht, J., Coffey, D., Anderson, C., Nash, M., Stein, M., Germain, M., Nair, V., Lippa, C., Beyer, J., Richardson, B., Moore, N., Vidic, T., Igleburger, J., Levey, A., Edwards, K., Steiner, D., Chang, F., Long, J., Turner, R., Apter, J., Barnhart, B., Nash, M., Schwartz, R., Shatz, R., Robillard, A., Garcia, A., Kohlenberg, C., Matthews, B., Chehrenama, H., Garrison, J., Shiwach, R., Jennings, D., Gazda, S., Davtian, A., Booker, J., Rovner, B., Goldenberg, J., Raj, A., Rosenberg, P., Watkins, F., Ingram, J., Chertkow, H., Yadalam, K., Applebaum, J., Biunno, M., Minagar, A., Rujescu, D., Randhawa, S., Dinnerstein, E., Margolin, D., Graff-Radford, N., Knopman, D., Antuono, P., Wilks, K., Du Preez, M., Lichtenstein, T., Barkhuizen, F., Thebaud, A., Liss, J., Mintzer, J., Dal-Bianco, P., Schmidt, R., Gold, S., Farmer, M., Agronin, M., Kohrman, B., Bozoki, A., Kapper, J., Winegarner, D., English, J., Grossman, H., Pomara, N., Murman, D., Spikol, L., Malhotra, S., Biber, M., Burkholder, J., Tramontano, G., Harris, J., Holub, R., Kudrow, D., Honeycutt, W., Waldman, S., Kittur, S., Stein, L., Gerard, G., Cohen, S., Goldstick, L., Chueh, D., Schaerf, F., Nasreddine, Z., Ellis, J., Nash, M., Shubin, R., Gywnn, M., Barker, J., Wendt, J., Mesulam, M., Sadowski, M., Quinn, J., Mikszewski, J., Tuchman, M., Foley, C., Borrie, M., Arnold, S., Rousseau, R., Oskooilar, N., Grosz, D., Wilcox, C., Kwentus, J., Sadowsky, C., Mega, M., Carlini, W., Ranjan, R., Bowman, M., Chakraburtty, A., Nardandrea, J., Sloan, B., Ott, B., Stoukides, J., Keegan, A., Bettinger, I., Grossberg, G., Goldstein, J., Itzcovich-Schuster, J., Winston, J., Feldman, R., Plopper, M., Ferencz, G., Ala, T., Vatakis, N., Montoya, L., Rossen, M., Stedman, M., Pasternak, S., Losk, S., Cohen, S., Ginsberg, P., Ng, B., Au, W., Dolnak, D., Tunell, G., Marotta, G., Ervin, J., Kalafer, M., Solomon, P., Ross, J., Scharre, C., Lobatz, M., Hubbard, R., Lerner, A., Ahern, G., Patry, D., DeCarli, C., Grill, J., Boxer, A., Brewer, J., Preda, A., Mastrianni, J., Burns, J., Jicha, G., Fishman, P., Chopra, A., Barbas, N., Ford, C., Lopez, O., Porsteinsson, A., Smith, A., Auchus, A., Rosenberg, R., Eschweiler, G., Riepe, M., von Arnim, C., Zamrini, E., Dekosky, S., Pendelbury, W., Asthana, S., Hart, D., Raskind, M., Trader, D., Dougherty, J., Vine, D., Carr, D., Tornabene, J., Keren, R., & van Dyck, C.
Venue
Neurology
Published
2018-03-06
Volume
90
Issue
10
Pages
e877-e886
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
OpenAlex
W2786374432
Cited by
44
References
16
FWCI
1.93
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab. https://app.cochat.ai/papers/10.1212/wnl.0000000000005060
The paper
Liu, E., Wang, D., Sperling, R., Salloway, S., Fox, N. C., Blennow, K., Scheltens, P., Schmidt, M. E., Streffer, J., Novak, G., Einstein, S., Booth, K., Ketter, N., Brashear, H. R., For the ELN115727-301/302 Investigator Group, ELN115727-301/302 Investigator Group, Chair, S. S., Sperling, R., Raskind, M., . . . van Dyck, C. (2018). Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab. Neurology. https://doi.org/10.1212/wnl.0000000000005060

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.